Cladribine Significantly Reduces Brain Atrophy in Patients with Multiple Sclerosis
Author: EMD Inc.(i) : Contact: emdserono.ca
Published: 2017-02-13 : (Rev. 2020-03-06)
Phase III CLARITY study data revealed significant reduction in brain atrophy in patients on short course of investigational Cladribine Tablets over two years.
- These findings reinforce and expand on the consistent and positive effect of Cladribine Tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability.
- Evidence shows that brain atrophy in general accumulates throughout the course of multiple sclerosis and is associated with disability progression.
Post hoc analysis of Phase III CLARITY study data recently published in Multiple Sclerosis Journal showed statistically significant reduction in brain atrophy in patients on a short course of investigational Cladribine Tablets over two years compared with patients receiving placebo.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating as EMD Serono in Canada, today announced the publication of the results of a post hoc analysis of the Phase III CLARITY study in Multiple Sclerosis Journal. The post hoc analysis showed that Cladribine Tablets reduced the annualised rate of brain volume loss - also known as brain atrophy - compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS).
In addition, the analysis found that patients with lower rates of brain atrophy showed the highest probability of remaining free from disability progression at two years.1 This supports existing findings that increased brain volume loss over time is associated with worse clinical outcomes such as increased disability progression and cognitive changes, in patients with multiple sclerosis.
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. Although many treatments exist there is a need for an effective therapy without the risks associated with continuous immunosuppression and which reduces the need for frequent switches.
"Evidence shows that brain atrophy in general accumulates throughout the course of multiple sclerosis and is associated with disability progression. This analysis is important because it confirms the link between reduced brain atrophy and reduced disability progression found in the CLARITY study," said Nicola De Stefano, lead author of the publication and Associate Professor of Neurology, Department of Medicine, Surgery and Neuroscience, University of Siena.
The CLARITY study was a two-year (96-week), randomised, double-blind, placebo-controlled Phase III study of Cladribine Tablets in 1,326 people with RRMS. The CLARITY study primary (rate of relapse at 96 weeks) and key secondary endpoints (proportion of patients who were relapse free and the time to sustained progression of disability) were met. These outcomes and safety results were published in The New England Journal of Medicine.
The brain atrophy analysis evaluated the effect of Cladribine tablets on brain volume loss (BVL) over 2 years in RMS and the association of BVL with confirmed disability progression in 1,025 (77.3%) of the patients in CLARITY.
- The mean percentage brain volume loss per year was significantly reduced in patients treated with Cladribine Tablets 3.5 mg/kg (--0.56%±0.68, p=0.010, n=336) and 5.25 mg/kg (--0.57%±0.72, p=0.019, n=351) compared with patients treated with placebo (--0.70%±0.79, n=338).
- The risk of disability progression was also significantly lower in patients treated with Cladribine Tablets 3.5 mg/kg (HR 0.63, 95% CI 0.438, 0.894; p=0.010) and 5.25 mg/kg (HR 0.58, 95% CI 0.406, 0.833; p=0.003) than in those treated with placebo.
- After adjusting for treatment group, percentage brain volume loss per year showed a significant correlation with the cumulative probability of disability progression in the overall study population (HR 0.67, 95% CI 0.571, 0.787; p<0.0001).
"These findings reinforce and expand on the consistent and positive effect of Cladribine Tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability, and further our resolve to make this investigational therapy available for patients living with RRMS," said Steven Hildemann, MD, PhD, Global Chief Medical Officer and Head of Global Medical Affairs and Safety, Merck KGaA, Darmstadt, Germany.
"All treatments for relapsing MS disease hope to minimize inflammation, which is believed to contribute both to cognitive and physical disability progression, which in turn correlates with the irreversible loss of brain tissue that can be measured by MRI as brain atrophy. Showing now that cladribine tablets' effects on reducing attacks is also associated with reduced brain atrophy indicates that the treatment is getting at the heart of the disease;" said Mark Freedman MD, Director, Multiple Sclerosis Research Unit at the Ottawa Hospital and investigator for the CLARITY trial.
CLARITY study design The CLARITY study was a two-year (96-week), randomised, double-blind, placebo-controlled, international study. It randomised 1,326 patients with relapsing remitting MS according to the revised McDonald criteria. Study participants were randomised to one of three different treatment groups consisting of two different dose regimens of Cladribine Tablets or matching placebo tablets (1:1:1 ratio).
- The primary endpoint of the CLARITY study was the relapse rate over 96 weeks.
- Secondary endpoints included MRI endpoints, proportion of subjects relapse-free and disability progression at 96 weeks.
Lymphopenia was the most commonly reported adverse event (AE) in patients treated with Cladribine Tablets.
The incidence of infections was 48.3% with Cladribine Tablets and 42.5% with placebo, with 99.1% and 99.0% rated mild-to-moderate by investigators.
Cladribine Tablets is an investigational short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of MS. Cladribine Tablets is currently under clinical investigation and not yet approved for the treatment for any use in the United States, Canada and Europe. In July 2016, the European Medicines Agency (EMA) accepted for review the Marketing Authorisation Application (MAA) of Cladribine Tablets for the treatment of relapsing remitting multiple sclerosis.
The clinical development program for Cladribine Tablets includes:
- The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study and its extension: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of Cladribine Tablets as a monotherapy in patients with RRMS and its two-year extension designed to provide data on the long-term safety and efficacy of extended administration of Cladribine Tablets for up to four years.
- The ORACLE MS (ORAl CLadribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of Cladribine Tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS).
- The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding Cladribine Tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy.
- PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Studies) study: interim long-term follow-up data from the prospective registry, PREMIERE, to evaluate the safety and efficacy of Cladribine Tablets. The follow-up will consist of over 10,000 patient years of exposure in total, with follow-up in some patients exceeding eight years at completion.
(i)Source/Reference: EMD Inc.. Disabled World makes no warranties or representations in connection therewith. Content may have been edited for style, clarity or length.
- 1 - Cladribine Significantly Reduces Brain Atrophy in Patients with Multiple Sclerosis : EMD Inc. (2017/02/13)
- 2 - New Multiple Sclerosis Treatment Clinical Trial Begins Enrollment : The Immune Tolerance Network; Benaroya Research Institute at Virginia Mason. (2020/01/07)
- 3 - Stigma Increases Risk of Depression for People with Multiple Sclerosis : Penn State (2018/03/01)
- 4 - Fumaric Acid Salts for Psoriasis May Help Multiple Sclerosis : Ruhr-University Bochum (2011/03/07)
- 5 - New Drug Cladribine for Multiple Sclerosis Shows Promise : Queen Mary, University of London (2010/01/20)
- 6 - Naltrexone Treats Multiple Sclerosis - But Sufferers Can't Get it : Cris Kerr (2009/02/27)
- 7 - $7M MS Progression Cohort to Research Multiple Sclerosis in Canada : Multiple Sclerosis Society of Canada (2017/03/31)
• Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.
• Please report outdated or inaccurate information to us.